Kiniksa Pharmaceuticals International Cash Flow Statement
NASDAQ: KNSAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Kiniksa Pharmaceuticals International free cash flow
In fiscal 2025, Kiniksa Pharmaceuticals International generated $138.0 million of operating cash flow and spent $1.6 million on capital expenditures. That left free cash flow of $136.4 million, a free-cash-flow margin of 20.1% of revenue. Free cash flow was up 436.8% from the prior year's $25.4 million.
Summary generated from market data by MetaCap's automated system. Methodology
Kiniksa Pharmaceuticals International cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | 59.01M | -43.19M | 14.08M | 183.36M | -157.92M | -161.38M | -161.87M | -103.23M | -64.87M |
| Net Income growth (YoY) | — | -406.68% | -92.32% | — | — | — | — | — | — |
| Depreciation & Amortization | 1.55M | 1.70M | 2.34M | 2.40M | 2.35M | 2.40M | 2.07M | 286.00K | 28.00K |
| Stock-Based Compensation | 37.00M | 30.69M | 27.15M | 25.12M | 25.17M | 20.88M | 15.08M | 5.70M | 897.00K |
| Change in Working Capital | 12.76M | 38.56M | -7.65M | -16.14M | 7.06M | 2.49M | -1.09M | 13.33M | 3.93M |
| Operating Cash Flow | 137.99M | 25.69M | 13.30M | 5.81M | -126.30M | -136.53M | -158.37M | -81.01M | -50.22M |
| Capital Expenditures | -1.57M | -277.00K | -130.00K | -105.00K | -415.00K | -283.00K | -3.20M | -5.29M | -69.00K |
| Investing Cash Flow | -188.99M | 37.67M | -29.56M | -8.08M | 128.63M | -23.44M | 49.21M | -239.20M | -69.00K |
| Dividends Paid | — | — | — | — | — | — | — | 0 | 0 |
| Financing Cash Flow | 33.02M | 12.27M | 1.50M | 2.52M | 5.88M | 227.09M | 84.11M | 346.74M | 39.87M |
| Net Change in Cash | -17.98M | 75.63M | -14.76M | 245.00K | 8.22M | 67.11M | -25.05M | 26.53M | -10.41M |
| Free Cash Flow | 136.42M | 25.41M | 13.17M | 5.70M | -126.71M | -136.81M | -161.57M | -86.30M | -50.29M |
This table shows 9 annual periods of Kiniksa Pharmaceuticals International's cash flow statement, from FY 2025 back to FY 2017, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow KNSA's reporting calendar. What is a cash flow statement?